Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 10,510 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Kidney Stone
Interventions: Low Oxalate Diet before Weight Loss, Oral load of oxalate and sucralose before Weight Loss, Optifast VLCD Program, Optifast VLCD Transition Phase, Low Oxalate Diet after Weight Loss, Oral load of oxalate and sucralose after Weight Loss; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: TAR-200, Mitomycin C, Gemcitabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 29
States / cities: Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more

Conditions: Femur Fracture
Interventions: Single Distal Femur Implant, Dual Distal Femur Implant; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer Female
Interventions: tamoxifen, letrozole, anastrozole, or exemestane, Patient reported outcomes; Drug · Behavioral
Lead sponsor: Shayna Showalter, MD; Other
Eligibility: 65 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Driving Behavior
Interventions: Hazard Perception Training, Vehicle Maintenance Training, Attention Maintenance Training; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 15 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hyperlipidemias
Interventions: Non-visit Based Intervention, Visit-Based Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 75 Years
Enrollment: 1,950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Urologic Surgical Procedures, Carbohydrate Loading, Preoperative Care
Interventions: UCAN SuperStarch, Gatorade; Dietary Supplement
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Alzheimer Dementia, Presenile Alzheimer Dementia, Aging
Interventions: Personalized tDCS, Active-Sham; Other
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 65 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Roslindale, Massachusetts

Conditions: Chronic Low-back Pain, Anxiety, Depression
Interventions: EaseVRx, Sham VR; Device
Lead sponsor: AppliedVR Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Van Nuys, California

Conditions: Cancer
Interventions: exercise (walking), plasma samples, blood draw; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Boulder, Colorado • Middletown, New Jersey + 7 more

Conditions: B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, High-grade B Cell Lymphoma, Mediastinal Large B-cell Lymphoma
Interventions: 19(T2)28z1xx TRAC T cell; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions: alemtuzumab, ofatumumab, biopsy; Biological · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lipomatosis, Multiple Symmetrical
Interventions: Metreleptin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 60 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
Interventions: Venetoclax, Fludarabine, Busulfan, Azacitidine, Decitabine/cedazuridine; Drug
Lead sponsor: Jacqueline Garcia, MD; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV
Interventions: Predictive Analytics and Clinical Decision Support; Other
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 16
States / cities: Fremont, California • Oakland, California • Oceanside, California + 13 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Pirtobrutinib, Positron Emission Tomography, Venetoclax, Echocardiography, Multigated Acquisition Scan, Biopsy; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Melanoma, Skin Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 4,082 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: HPV, Oropharyngeal Squamous Cell Carcinoma
Interventions: Screening; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsing Multiple Sclerosis
Interventions: Ocrelizumab, Platform; Drug
Lead sponsor: Georgia State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation; Genetic · Radiation
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 10
States / cities: Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more

Conditions: Alcohol Use Disorder
Interventions: Citicoline (cytidine diphosphate-choline), Placebo oral capsule; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 16 Years to 22 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions: Carboplatin, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Nivolumab; Drug · Other · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Duarte, California • New Haven, Connecticut • Houston, Texas + 1 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 OA investigational vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 60 Years and older
Enrollment: 1,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 18
States / cities: Mobile, Alabama • Phoenix, Arizona • Riverside, California + 15 more

Search by objective public record fields.

Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

Dual Implant Versus Single Implant Distal End of Femur

Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer

Washington State Driving Intervention Research Study

Centralized Prescribing for Statins

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Carbohydrate Ingestion Prior to Surgery (CIPS)

Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease

EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain

Researching the Effect of Aerobic Exercise on Cancer

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

A Model for Genetic Susceptibility: Melanoma

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

Effects of Ocrevus in Relapsing Multiple Sclerosis

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Citicoline in Youth Alcohol Use Disorder

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above